TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03899181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Translumbosacral Neuromodulation Therapy (TNT)
Description: A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Translumbosacral Neuromodulation Therapy (TNT)
Description: A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TNT Therapy
Description: This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
Study: NCT02739685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold
Description: Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Implantation of everolimus-eluting stent in chronic total occlusion
Study: NCT03584880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser disinfection
Description: Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pseudo diode laser disinfection
Description: Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
Study: NCT04519242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon.
Study: NCT00653939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin
Description: Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT01775631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT00993811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision
Description: novel device for adult male circumcision
Study: NCT03136315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INFERNAL Intervention
Description: The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
Study: NCT03315767

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ARFI-elastography and portal vein flow measurement
Description: Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HVPG-measurement
Description: Evaluation of Portal Hypertension by HVPG-measurement
Study: NCT00653939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT01519193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for violent offenders (NETvo)
Description: During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
Study: NCT01443624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: critical care patients venofer
Description: 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
Study: NCT04185116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Optic System (Olympus VISERA Elite II 3D)
Description: Use of the 3D Optic System Olympus VISERA Elite II 3D

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Optic System (Olympus VISERA Elite II 3D)
Description: Use of the 3D Optic System Olympus VISERA Elite II 3D
Study: NCT02194374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROR1R-CAR-T Cell Infusion
Description: Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3.
Study: NCT01238484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: shoe modification home stretching exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
Study: NCT00870376

Intervention type: OTHER
Intervention: biomarkers
Description: To define a biomarker or combination of overactive bladder syndrome
Study: NCT01380626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: strength and endurance training, 5 time per week.
Study: NCT01040117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory-motor Integration Training
Description: Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neurorehabilitation treatment
Description: The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position.
Study: NCT05926518

Intervention type: PROCEDURE
Intervention: blood sampling
Description: Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.

Intervention type: PROCEDURE
Intervention: blood sampling
Description: Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
Study: NCT02878798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: Oral topiramate at a target dose of 50mg twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: overencapsulated placebo of identical color, shape and packaging to topiramate
Study: NCT02377661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil, amlodipine, hydrochlorothiazide
Description: Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
Study: NCT04713397

Intervention type: DIAGNOSTIC_TEST
Intervention: Leg Length Discrepancy Scoliometer Test
Description: A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Leg Length Discrepancy Scoliometer Test
Description: A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated.
Study: NCT03891238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
Study: NCT00932061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Acupuncture
Description: Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.
Study: NCT03811860

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lithium level
Description: The level of lithium in the serum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lithium level
Description: The level of lithium in the serum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Creatinine
Description: The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Creatinine
Description: The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
Study: NCT03706248

Intervention type: OTHER
Intervention: Blood Draw
Description: 20 ml of blood will be drawn from subjects via venipuncture

Intervention type: OTHER
Intervention: Blood Draw
Description: 20 ml of blood will be drawn from subjects via venipuncture
Study: NCT01715441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and irinotecan combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan monotherapy
Study: NCT03309176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate 10 MG
Description: Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair step protocol without Medroxyprogesterone Acetate
Description: No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
Study: NCT05343767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Wellness Low-Glu low dose
Description: The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Wellness Low-Glu high dose
Description: The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: A total dose of 2000 mg was administered per day.
Study: NCT02711228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Immune Globulin (Human) (Hizentra)
Description: Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
Study: NCT04235296

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: epidermal growth factor
Description: Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell conditioned medium-derived pleiotropic factor
Description: Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
Study: NCT03479333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short implant
Description: Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implant with sinus lift
Description: First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
Study: NCT01110642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Topical lovastatin applied to red, rashy areas two times daily for 12 months
Study: NCT02009540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin injected to bladder body
Description: arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injected into trigone
Description: Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
Study: NCT02508818

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular measurements
Study: NCT00125528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid
Study: NCT04343105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pecto-intercostal plane block
Description: under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pecto-intercostal plane block
Description: under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles